[go: up one dir, main page]

HUS2100013I1 - Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények - Google Patents

Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények

Info

Publication number
HUS2100013I1
HUS2100013I1 HUS2100013C HUS2100013C HUS2100013I1 HU S2100013 I1 HUS2100013 I1 HU S2100013I1 HU S2100013 C HUS2100013 C HU S2100013C HU S2100013 C HUS2100013 C HU S2100013C HU S2100013 I1 HUS2100013 I1 HU S2100013I1
Authority
HU
Hungary
Prior art keywords
conjugates
interleukin
methods
diphtheria toxin
compositions based
Prior art date
Application number
HUS2100013C
Other languages
English (en)
Original Assignee
Scott & White Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott & White Memorial Hospital filed Critical Scott & White Memorial Hospital
Publication of HUS2100013I1 publication Critical patent/HUS2100013I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUS2100013C 2006-09-07 2021-04-22 Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények HUS2100013I1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84347106P 2006-09-07 2006-09-07
US93277207P 2007-06-01 2007-06-01
EP17151480.5A EP3207941B3 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

Publications (1)

Publication Number Publication Date
HUS2100013I1 true HUS2100013I1 (hu) 2021-05-28

Family

ID=39157851

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17151480A HUE048356T2 (hu) 2006-09-07 2007-09-07 Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények
HUS2100013C HUS2100013I1 (hu) 2006-09-07 2021-04-22 Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE17151480A HUE048356T2 (hu) 2006-09-07 2007-09-07 Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények

Country Status (17)

Country Link
US (7) US7763242B2 (hu)
EP (4) EP4414036A3 (hu)
JP (7) JP5550905B2 (hu)
AU (1) AU2007293047B2 (hu)
CA (5) CA3007075C (hu)
CY (3) CY1119654T1 (hu)
DK (2) DK2063907T3 (hu)
ES (3) ES2781402T7 (hu)
FR (1) FR21C1017I2 (hu)
HU (2) HUE048356T2 (hu)
LT (2) LT3207941T (hu)
LU (1) LUC00206I2 (hu)
NL (1) NL301103I2 (hu)
PL (2) PL2063907T3 (hu)
PT (1) PT3207941T (hu)
SI (1) SI3207941T1 (hu)
WO (1) WO2008030539A2 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
LT3207941T (lt) 2006-09-07 2020-04-10 Scott & White Memorial Hospital Būdai ir kompozicijos difterijos toksino ir interleukino 3 konjugatų pagrindu
US8129341B2 (en) 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
EP2352526A1 (en) * 2008-09-19 2011-08-10 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
EP2536430B1 (en) * 2010-02-17 2016-12-14 CSL Limited Compositions and methods for targeting type 1 interferon producing cells
US9254310B2 (en) 2010-06-17 2016-02-09 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
JP6327855B2 (ja) 2010-09-03 2018-05-23 アッヴィ・ステムセントルクス・エル・エル・シー 新規モジュレータ及びその使用法
CA2820885A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
JP6089047B2 (ja) 2012-02-24 2017-03-01 アッヴィ・ステムセントルクス・エル・エル・シー Ｄｌｌ３モジュレーター及び使用方法
PH12020500604A1 (en) 2012-02-24 2023-06-14 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
SMT201900339T1 (it) 2013-02-22 2019-07-11 Medimmune Ltd Coniugati anticorpo anti-dll3/pbd e loro usi
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
WO2015051304A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarkers and their use in treatment of cancer
JP6515111B2 (ja) 2013-11-06 2019-05-22 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗クローディン抗体および使用方法
CA2932476A1 (en) 2013-12-12 2015-06-18 Stemcentrx, Inc. Novel anti-dpep3 antibodies and methods of use
BR112016018891A2 (pt) 2014-02-21 2017-10-10 Abbvie Stemcentrx Llc anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
PT3137114T (pt) 2014-04-30 2021-02-26 Pfizer Conjugados anticorpo-fármaco anti-ptk7
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
CA3021098A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
US11149047B2 (en) 2017-10-30 2021-10-19 Aptose Biosciences, Inc. Aryl imidazoles for treatment of cancer
EP3784270A1 (en) 2018-04-27 2021-03-03 Stemline Therapeutics Inc. Methods of treating an autoimmune disease with a human interleukin-3 (il-3)-diphtheria toxin conjugate (dt-il3)
EP3802834A4 (en) * 2018-05-30 2022-08-03 The Governing Council of the University of Toronto METHODS AND KITS FOR IDENTIFYING A PROTEIN RELATED TO RECEPTOR-LIGAND INTERACTIONS
CN120960440A (zh) 2018-10-31 2025-11-18 斯坦林治疗公司 用白喉毒素-人白细胞介素-3缀合物与其它药剂组合治疗骨髓增生性肿瘤的组合治疗方法
WO2020112642A1 (en) 2018-11-30 2020-06-04 Stemline Therapeutics, Inc. Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate
WO2021099573A1 (en) * 2019-11-21 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml)
JP7630625B2 (ja) 2020-12-10 2025-02-17 ステムライン セラピューティクス，インコーポレーテッド 改善された凍結乾燥製剤

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
ATE25197T1 (de) 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
GB8628068D0 (en) 1986-11-24 1986-12-31 Unilever Plc Aqueous gel comprising carrageenan
EP0550436A1 (en) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
ATE200493T1 (de) 1990-03-02 2001-04-15 Boston Medical Ct Corp Verbesserte chimäre toxine
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4140121C2 (de) 1991-12-05 1994-06-30 Manfred Mueller Verfahren zum Herstellen von gefaßten, gegossenen Schmuckstücken
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
WO1996038571A2 (en) * 1995-05-31 1996-12-05 Regents Of The University Of Minnesota Recombinant polypeptide cytotoxins for cancer treatment
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US20040013664A1 (en) 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
CA2393132A1 (en) 1999-12-03 2001-06-07 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Dendritic cell-specific antibodies
JP2004509835A (ja) 2000-03-06 2004-04-02 ユニヴァーシティ　オブ　ケンタッキー　リサーチ　ファンデーション 血液癌前駆細胞を障害する方法およびその関連化合物
WO2002069904A2 (en) 2001-03-02 2002-09-12 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
IL157706A0 (en) 2001-03-02 2004-03-28 Medimmune Inc METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
LT3207941T (lt) * 2006-09-07 2020-04-10 Scott & White Memorial Hospital Būdai ir kompozicijos difterijos toksino ir interleukino 3 konjugatų pagrindu
AU2014201901B2 (en) 2006-09-07 2016-05-05 Scott & White Healthcare Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
FR2982762B1 (fr) 2011-11-21 2014-12-12 Patrick Arnoux Appareil de brossage de dents a multiples systemes rotatifs de brossage
US20150038679A1 (en) 2012-02-29 2015-02-05 Ambrx, Inc. Interleukin-3 Polypeptide Conjugates and Their Uses
US11899690B2 (en) 2019-09-02 2024-02-13 Nippon Telegraph And Telephone Corporation Data analytical processing apparatus, data analytical processing method, and data analytical processing program

Also Published As

Publication number Publication date
EP2063907A4 (en) 2011-08-31
JP6654660B2 (ja) 2020-02-26
EP4414036A2 (en) 2024-08-14
US11130792B2 (en) 2021-09-28
CA2698595A1 (en) 2008-03-13
PT3207941T (pt) 2020-04-02
NL301103I1 (nl) 2021-06-17
CA3153438C (en) 2024-03-12
DK3207941T6 (da) 2020-11-09
WO2008030539A3 (en) 2009-04-09
NL301103I2 (nl) 2021-08-02
WO2008030539A2 (en) 2008-03-13
JP2018135378A (ja) 2018-08-30
EP3520806B1 (en) 2024-03-20
CA2698595C (en) 2016-07-26
LUC00206I2 (hu) 2022-10-07
US20190169251A1 (en) 2019-06-06
JP2016155830A (ja) 2016-09-01
LT3207941T (lt) 2020-04-10
JP5550905B2 (ja) 2014-07-16
LTC3207941I2 (hu) 2022-10-10
AU2007293047B2 (en) 2014-01-09
JP2014144967A (ja) 2014-08-14
US20220235108A1 (en) 2022-07-28
CA3153438A1 (en) 2008-03-13
CA2923381A1 (en) 2008-03-13
ES2781402T7 (es) 2021-06-09
EP2063907B1 (en) 2017-08-09
US9181317B2 (en) 2015-11-10
US20090232767A1 (en) 2009-09-17
US20180022788A1 (en) 2018-01-25
CA3053981A1 (en) 2008-03-13
AU2007293047A1 (en) 2008-03-13
US9631006B2 (en) 2017-04-25
ES2646545T3 (es) 2017-12-14
US7763242B2 (en) 2010-07-27
CY1119654T1 (el) 2019-07-10
EP4414036A3 (en) 2024-10-09
US12180257B2 (en) 2024-12-31
SI3207941T1 (sl) 2020-08-31
PL3207941T6 (pl) 2020-11-16
JP2020079260A (ja) 2020-05-28
JP2024088720A (ja) 2024-07-02
JP2010502712A (ja) 2010-01-28
FR21C1017I1 (hu) 2021-07-02
CY1123035T1 (el) 2021-09-14
EP3207941B1 (en) 2019-12-25
EP2063907A2 (en) 2009-06-03
EP3207941A1 (en) 2017-08-23
CY2021011I1 (el) 2021-10-15
HUE048356T2 (hu) 2020-07-28
JP2022065089A (ja) 2022-04-26
JP6336500B2 (ja) 2018-06-06
EP3207941B3 (en) 2020-08-19
CA3007075A1 (en) 2008-03-13
US8470307B2 (en) 2013-06-25
US20130315860A1 (en) 2013-11-28
LTPA2021507I1 (hu) 2021-06-10
US20160024167A1 (en) 2016-01-28
CA3053981C (en) 2022-07-12
JP5902223B2 (ja) 2016-04-13
DK2063907T3 (da) 2017-11-13
CY2021011I2 (el) 2021-10-15
FR21C1017I2 (fr) 2022-04-22
US10259853B2 (en) 2019-04-16
PL2063907T3 (pl) 2018-06-29
CA3007075C (en) 2019-10-15
US20080138313A1 (en) 2008-06-12
DK3207941T3 (da) 2020-03-30
ES2987072T3 (es) 2024-11-13
EP3520806A1 (en) 2019-08-07
PL3207941T3 (pl) 2020-07-27
ES2781402T3 (es) 2020-09-01

Similar Documents

Publication Publication Date Title
HUS2100013I1 (hu) Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények
EP2182922A4 (en) ANTIGEN-ADJUVANS COMPOSITIONS AND METHOD
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
ZA201203709B (en) Immunogenic compositions and methods
EP2041175A4 (en) TARGETED IMMUNOJUGATE
LT1988910T (lt) Akriloiloksietilfosforilcholiną turintys polimero konjugatai ir jų gavimo būdas
IL227934A0 (en) Immunogenic preparation
IL193922A0 (en) Anti-tat226 antibodies and immunoconjugates
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
ZA201001206B (en) Saccharide-containing protein conjugates and uses thereof
EP2370472A4 (en) LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES
GB0721291D0 (en) Methods and compositions
IL195561A0 (en) Methods and compositions for targeting hepsin
GB0719526D0 (en) Compositions and methods
IL199718A0 (en) Peptide-complement conjugates
GB0617171D0 (en) Novel compositions and methods
EP2010141A4 (en) NUCLEOTIDE COMPOSITIONS HAVING HIGH DEPOSITS AND USES THEREOF
GB0606416D0 (en) Immunogenic composition
GB0501348D0 (en) Compositions and methods
GB0602688D0 (en) Conjugates
GB0625230D0 (en) Compositions and methods
GB0607565D0 (en) Methods and compositions
GB0616269D0 (en) Methods and compositions
SG10201403055VA (en) Conjugation methods
GB0724549D0 (en) Compositions and methods